Tenaya Therapeutics is trading 11.02% higher at $0.41 in pre-market on November 2, 2026, versus the October 30 close of $0.37; no clear new company announcement explaining the move was identified. - A report about Tenaya’s Alnylam collaboration appeared around the weekend, but the partnership was announced in March and its upfront payment was received in April, so it is not evidence of a fresh catalyst. - Broader market futures were modestly higher, but that alone does not establish the reason for the move.